Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") of a class action securities ...

Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

To join the ESSA Pharma Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=34133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on ...